Philip Reilly will officially join Third Rock Ventures, LLC as a partner in the Boson-based venture capital firm that specializes in life science investing.

Reilly is the former CEO and chairman of the board at Interleukin Genetics Inc., a Waltham-based maker of genetics tests for personalized health care, where he served at the helm from 2000 to 2006.

Prior to his time at Interleukin, Reilly served as executive director of the Eunice Kennedy Shriver Center for Mental Retardation, Inc.

According to the firm, Reilly will focus on companies developing treatments for genetic disorders.

Third Rock also announced that Greg Verdine, director of the Chemical Biology Initiative at Dana Farber Cancer Institute would be joining the firm as partner, along with Craig Greeves, formerly of Cubist Pharmaceuticals, who will serve as a recruiting partner.

Founded in 2007, Third Rock Ventures has $378 million under management